SOPHiA GENETICS Provides an Update on its DEEP-Lung-IV Multimodal Clinical Study at ASCO 2022

- Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer
  
  Nearly 20 participating sites activated worldwide with over 500 patients recruited to date. Early findings conceptually validate the potential for multimodal signatures to predict response to immuno-chemotherapy with promising first results